| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Glioblastoma (GM) is highly invasive due to the expression of proteases including urokinase-type plasminogen activator (uPA). A new recombinant Sendai virus (rSeV) showing uPA-specific cell-to-cell fusion activity [rSeV/dMFct14 (uPA2)] was shown to be effective for GM treatment, especially with the interferon-β (IFN-β) gene integration. There were marked infiltration of CD8 T cell, CD4 T cell, and CD11b+ cells in the brain tumor tissues. Flt3-L was also highly positive in the tumor tissues treated with rSeV/dMFct14 (uPA2)/ IFNβ, which was considered to be the molecular background of the prominent immunogeneicity. There were no adverse events observed in the long-survived rats. Therefore, these results suggest that rSeV/dMFct14 (uPA2)/ IFNβ may have a significant potential to improve the survival of GM patients in a clinical setting.
|
